Hanne Trap Wolf, Tine Brink Henriksen, Mads Langager Larsen, Anja Pinborg, Hanne Kristine Hegaard, Jesper Sune Brok & Lene Drasbek Huusom
Ugeskr Læger 2020;182:V06200441
Children born preterm have an increased risk of severe morbidity, e.g. cerebral palsy (CP), compared to children born at term. CP cannot be treated, which is why a prophylactic approach is essential, as argued in this review. Six randomised controlled trials (RCTs) have provided data on MgSO4 treatment as CP neuroprotection in preterm birth, including a new RCT from Denmark. Recently, an updated meta-analysis with trial sequential analysis detected a significant neuroprotective effect of MgSO4 treatment in preterm birth. There is now sufficient evidence, that MgSO4 treatment should be used as neuroprotection in preterm birth.